OTC Markets Group Welcomes ONWARD Medical N.V. to OTCQX
OTC Markets Group announced that ONWARD Medical N.V., a medical technology company developing spinal cord stimulation therapies, has begun trading on the OTCQX market under the symbols 'ONWRF' and 'ONWRY'. The company, already listed on Euronext Brussels (ONWD), aims to expand access to US investors through this move.
ONWARD Medical has also established a sponsored Level 1 ADR program with BNY as the depositary bank, where one ADR represents one ordinary share. The company's CEO, Dave Marver, highlighted this as a strategic step toward a potential US IPO and improved liquidity. To qualify for OTCQX, ONWARD Medical met high financial standards, corporate governance requirements, and securities law compliance.
OTC Markets Group ha annunciato che ONWARD Medical N.V., un'azienda di tecnologia medica specializzata nello sviluppo di terapie di stimolazione del midollo spinale, ha iniziato a essere quotata sul mercato OTCQX con i simboli 'ONWRF' e 'ONWRY'. La società, già presente su Euronext Brussels (ONWD), intende ampliare l'accesso agli investitori statunitensi con questa iniziativa.
ONWARD Medical ha inoltre istituito un programma ADR sponsorizzato di Livello 1 con BNY come banca depositaria, dove un ADR rappresenta una azione ordinaria. Il CEO dell'azienda, Dave Marver, ha sottolineato che questa mossa rappresenta un passo strategico verso una possibile IPO negli Stati Uniti e un miglioramento della liquidità. Per qualificarsi per l'OTCQX, ONWARD Medical ha soddisfatto elevati standard finanziari, requisiti di governance aziendale e conformità alle normative sui titoli.
OTC Markets Group anunció que ONWARD Medical N.V., una empresa de tecnología médica que desarrolla terapias de estimulación de la médula espinal, ha comenzado a cotizar en el mercado OTCQX bajo los símbolos 'ONWRF' y 'ONWRY'. La compañía, ya listada en Euronext Brussels (ONWD), busca ampliar el acceso a inversores estadounidenses con este movimiento.
ONWARD Medical también ha establecido un programa ADR patrocinado de Nivel 1 con BNY como banco depositario, donde un ADR representa una acción ordinaria. El CEO de la empresa, Dave Marver, destacó que este es un paso estratégico hacia una posible oferta pública inicial (IPO) en EE.UU. y una mejor liquidez. Para calificar para OTCQX, ONWARD Medical cumplió con altos estándares financieros, requisitos de gobernanza corporativa y cumplimiento de la legislación de valores.
OTC Markets Group는 척수 자극 치료법을 개발하는 의료기술 회사인 ONWARD Medical N.V.가 OTCQX 시장에 'ONWRF'와 'ONWRY' 심볼로 거래를 시작했다고 발표했습니다. 이 회사는 이미 유로넥스트 브뤼셀(ONWD)에 상장되어 있으며, 이번 조치를 통해 미국 투자자 접근성을 확대하려고 합니다.
ONWARD Medical은 또한 BNY를 예탁은행으로 하는 스폰서드 레벨 1 ADR 프로그램을 설립했으며, 1 ADR은 보통주 1주를 나타냅니다. 회사의 CEO인 Dave Marver는 이번 조치를 미국 IPO 가능성과 유동성 개선을 위한 전략적 단계로 강조했습니다. OTCQX 자격을 얻기 위해 ONWARD Medical은 높은 재무 기준, 기업 지배구조 요건 및 증권법 준수를 충족했습니다.
OTC Markets Group a annoncé que ONWARD Medical N.V., une entreprise de technologie médicale développant des thérapies de stimulation de la moelle épinière, a commencé à être cotée sur le marché OTCQX sous les symboles 'ONWRF' et 'ONWRY'. La société, déjà cotée à Euronext Bruxelles (ONWD), vise à élargir l’accès aux investisseurs américains grâce à cette démarche.
ONWARD Medical a également mis en place un programme ADR de niveau 1 parrainé avec BNY en tant que banque dépositaire, où un ADR représente une action ordinaire. Le PDG de l’entreprise, Dave Marver, a souligné qu’il s’agissait d’une étape stratégique vers une éventuelle introduction en bourse aux États-Unis et une meilleure liquidité. Pour être éligible à l’OTCQX, ONWARD Medical a respecté des normes financières élevées, des exigences de gouvernance d’entreprise et la conformité aux lois sur les valeurs mobilières.
OTC Markets Group gab bekannt, dass ONWARD Medical N.V., ein Medizintechnikunternehmen, das Therapien zur Rückenmarkstimulation entwickelt, nun unter den Symbolen 'ONWRF' und 'ONWRY' am OTCQX-Markt gehandelt wird. Das Unternehmen, bereits an der Euronext Brüssel (ONWD) gelistet, möchte durch diesen Schritt den Zugang für US-Investoren erweitern.
ONWARD Medical hat zudem ein gesponsertes Level-1-ADR-Programm mit BNY als Depotbank eingerichtet, wobei ein ADR eine Stammaktie repräsentiert. Der CEO des Unternehmens, Dave Marver, bezeichnete dies als strategischen Schritt in Richtung eines möglichen US-Börsengangs (IPO) und verbesserter Liquidität. Um sich für OTCQX zu qualifizieren, erfüllte ONWARD Medical hohe finanzielle Standards, Anforderungen an die Unternehmensführung und die Einhaltung von Wertpapiergesetzen.
- Expanded access to US investor base through OTCQX listing
- Strategic positioning for potential US IPO
- Enhanced trading liquidity through ADR program
- Dual-listing status (Euronext Brussels and OTCQX) increases market presence
- None.
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ONWARD Medical N.V. (Euronext Brussels: ONWD; OTCQX: ONWRF, ONWRY), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities now trades on the OTCQX market.
ONWARD Medical N.V. begins trading today on OTCQX under the symbols “ONWRF and ONWRY.” US investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to expand access to US investors, many of whom have expressed interest in supporting ONWARD after learning about our mission to help people with spinal cord injury," said Dave Marver, CEO of ONWARD Medical. "Trading on OTCQX provides greater visibility and the opportunity for improved liquidity. We have also established a sponsored Level 1 ADR program to facilitate ease of trading for qualified US financial institutions, with our ADRs also trading on OTCQX. Broader US investor participation is an important step in our journey to a potential US IPO."
"We are proud to announce the addition of ONWARD Medical to the OTCQX Market," said Jason Paltrowitz, EVP of Corporate Services at OTC Markets. "This milestone not only marks a significant achievement for the company but also highlights the interplay between the European capital markets and U.S. investors seeking new investment opportunities."
Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.
ONWARD has also established a Level 1 ADR program to facilitate trading by qualified financial institutions. BNY acts as the depositary bank and transfer agent for the Company’s ADR program, with one ADR representing one ordinary share. The Company’s ADRs can also be traded on OTCQX under the ticker symbol ONWRY.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.
Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.
OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS™ are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
Subscribe to the OTC Markets RSS Feed
About ONWARD Medical
ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with SCI and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company’s ARC-EX System is now cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).
Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD).
For more information, visit ONWD.com and connect with us on LinkedIn and YouTube.
To be kept informed about the Company’s technologies, research studies, and the availability of therapies in your area, please complete this webform.
Media Contacts:
For OTC Markets Group Inquiries:
media@otcmarkets.com
+1 (212) 896-4428
For ONWARD Media Inquiries:
media@onwd.com
For ONWARD Investor Inquiries:
investors@onwd.com
FAQ
What are ONWARD Medical's new trading symbols on OTCQX?
How does ONWARD Medical's ADR program work on OTCQX?
What are the requirements for ONWARD Medical to trade on OTCQX?
What is ONWARD Medical's strategy behind joining OTCQX?
